Sports Nutrition Benefits of Weizmannia Coagulans BC99

Sports Nutrition Benefits of Weizmannia Coagulans BC99: a Randomized Controlled Trial on Muscle Function and Recovery in Healthy Participants

To evaluate the clinical efficacy of Weizmannia coagulans BC99 in young Chinese patients with exercise-induced muscle damage compared with placebo, and to explore its effects on inflammatory responses and intestinal microbiota.

Study Overview

• Status: Completed
• Conditions: College Students of the School of Physical Education
• Intervention / Treatment: Dietary supplement: Placebo; Dietary supplement: BC99

• Study Type: Interventional
• Enrollment (Actual): 72
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Henan
    • Luoyang, Henan, China, 471000
      • Wu Ying

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Healthy adults aged 19-35 years, with no restriction on sex;
2. Physically active individuals with regular daily exercise training intensity and duration;
3. No history of allergy to protein products;
4. Body weight ≥50 kg for male subjects and ≥45 kg for female subjects; body mass index (BMI), calculated as weight (kg) divided by height squared (m²), within the range of 19.0-24.0 kg/m²;
5. No history of cardiovascular or cerebrovascular diseases, hypertension, diabetes, hepatic or renal dysfunction, or other underlying diseases or metabolic disorders;
6. Willingness to comply with the study protocol and study restrictions, and voluntary provision of written informed consent to participate in the study.

Exclusion Criteria:

1. History of allergic constitution or immunodeficiency;
2. Blood donation or significant blood loss (≥200 mL) within 3 months prior to administration of the investigational product;
3. Presence of severe diseases of major organs, including the cardiovascular system, lungs, liver, or kidneys, as well as diabetes mellitus, severe thyroid disorders, metabolic diseases, malignant tumors, or severe immune system diseases;
4. Use of medications affecting the intestinal microbiota (including antibiotics, microecological preparations, intestinal mucosal protectants, traditional Chinese medicines, etc.) for more than one consecutive week within 1 month prior to screening;
5. Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo group; 3g dose of milk protein concentrate/pack, 8 packs per day	Dietary supplement: Placebo; The experimental phase of this study lasts 12 weeks and each participant will have 3 visits (week 0, week 6, week 12)
Experimental: BC99 group; 3g dose of milk protein concentrate with 6×109 Colony Forming Unit (CFU) W. coagulans BC99/pack, 8 packs per day	Dietary supplement: BC99; The experimental phase of this study lasts 12 weeks and each participant will have 3 visits (week 0, week 6, week 12)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pain evaluation	Visual analog scale (VAS) was used for assessing the pain level of muscle, ranging from 0 to 10 point (0 means no pain; 10 represent worst imaginable pain). VAS scores were recorded at 24h, 48h and 72h after the intense exercise work stress.	12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cortisol in plasma	This indicator was determined using commercially available assay kits (BYabscience, Nanjing, China).	12 weeks
Peptide YY in plasma	This indicator was determined using commercially available assay kits (BYabscience, Nanjing, China).	12 weeks

Collaborators and Investigators

• Sponsor: Wecare Probiotics Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2023
• Primary Completion (Actual): March 10, 2024
• Study Completion (Actual): March 28, 2024

Study Registration Dates

• First Submitted: December 24, 2025
• First Submitted That Met QC Criteria: December 24, 2025
• First Posted (Actual): January 8, 2026

Study Record Updates

• Last Update Posted (Actual): January 8, 2026
• Last Update Submitted That Met QC Criteria: December 24, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Other Study ID Numbers: WK20251225

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No